Skip to main content

Table 5 A brief list of HTL Epitopes to form the final structure of the vaccine

From: Development of a novel multi‑epitope vaccine against the pathogenic human polyomavirus V6/7 using reverse vaccinology

specie

epitopes

protein

antigenicity

allergenicity

IFN-γ

IL4

toxicity

epitope conservancy

hit (maximum identity %)

human homology

interacting MHC-II alleles

HPyV6

VAAQRRVLMLESTRQ

LTAg

0.8394

probable

non-allergen

positive

inducer

non-toxic

100

non-homologue

HLA-DRB1*04:10, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08

GLVNLVNYAVNYNRQ

VP2

0.7212

probable

non-allergen

positive

inducer

non-toxic

100

non-homologue

HLA-DRB1*08:06, HLA-DRB1*01:02, HLA-DRB1*08:13, HLA-DRB1*13:04, HLA-DRB1*08:01, HLA-DRB1*04:23

GRFFRVHFRQRRVKH

VP1

0.4931

probable

non-allergen

positive

inducer

non-toxic

100

non-homologue

HLA-DRB1*11:20, HLA-DRB1*11:14, HLA-DRB1*13:23, HLA-DRB1*08:04, HLA-DRB5*01:01, HLA-DRB5*01:05

SAGYIRAQGTPAGVE

VP1

0.8598

probable

non-allergen

positive

inducer

non-toxic

100

non-homologue

HLA-DRB1*09:01

HPyV7

DWNFVADFAADMELT

LTAg

1.2109

probable

non-allergen

positive

inducer

non-toxic

100

non-homologue

HLA-DRB3*01:01, HLA-DRB1*03:09, HLA-DRB1*03:05, HLA-DRB1*04:21

FEPGGVVMYDTQNLP

VP2

0.9125

probable

non-allergen

negative

inducer

non-toxic

100

non-homologue

HLA-DRB1*15:06, HLA-DRB1*04:02, HLA-DRB1*08:06, HLA-DRB1*15:02, HLA-DRB1*08:04, HLA-DRB1*08:13, HLA-DRB1*04:10, HLA-DRB1*08:01

FFRVHCRQRRIKHPY

VP1

0.4266

probable

non-allergen

negative

inducer

non-toxic

100

non-homologue

HLA-DRB5*01:05, HLA-DRB1*11:20, HLA-DRB1*11:14, HLA-DRB1*13:23